Teva Entitled To Exclusivity Period For Generic Pravachol – D.C. Court
This article was originally published in The Tan Sheet
Executive Summary
Teva's 180-day marketing exclusivity period for its generic equivalent of Bristol-Myers Squibb's Rx Pravachol (pravastatin) has "neither expired nor even commenced," District of Columbia District Court ruled Oct. 21
You may also be interested in...
Pravachol Exclusivity Case Remanded To FDA By Appeals Court
FDA needs to develop policy clarifying how the voluntary dismissal of a patent litigation proceeding impacts a generic drug maker's 180-day exclusivity period, according to a D.C. federal appeals court decision issued March 16
Teva Pravachol Exclusivity Loss Raises Bristol’s Stakes For Switch
Bristol-Myers Squibb has more to gain from an Rx-to-OTC switch of the cholesterol-lowering drug Pravachol (pravastatin) if an FDA decision allowing multiple generics on the market in April 2006 is upheld
Blame China? Experts Advise Congress, Industry Take A Wider View
The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say